Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited announced that its allogeneic cell therapy products, manufactured in the U.S. from U.S. donors, are designated as U.S. origin products and are not subject to tariffs on imported branded or patented pharmaceutical products. This designation, particularly for Ryoncil®, the only FDA-approved allogeneic mesenchymal stromal cell therapy, reinforces Mesoblast’s strategic positioning in the market by ensuring cost stability and regulatory compliance, potentially benefiting stakeholders by maintaining competitive pricing and access in the U.S. market.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines aimed at treating severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform to create therapies that release anti-inflammatory factors, significantly reducing damaging inflammatory processes. Mesoblast’s flagship product, Ryoncil®, is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The company is also developing additional cell therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 4,830,927
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.14B
For an in-depth examination of MSB stock, go to TipRanks’ Overview page.